Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 9 Similar Profiles
Neoplasms
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
TNF-Related Apoptosis-Inducing Ligand Receptors
Medicine & Life Sciences
Colorectal Neoplasms
Medicine & Life Sciences
Immunotherapy
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2017 2021
- 9 Active
Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local
Bayer HealthCare Pharmaceuticals, Inc.
10/18/18 → 5/19/21
Project: Research project
Research Output 2008 2018
A phase ii study of pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma
Mahalingam, D., Goel, S., Aparo, S., Arora, S. P., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Gutierrez, A., Coffey, M., Nawrocki, S. T., Nuovo, G. & Mita, M. M., Jun 1 2018, In : Cancers. 10, 6, 160.Research output: Contribution to journal › Article
gemcitabine
Adenocarcinoma
Oncolytic Virotherapy
Mammalian orthoreovirus 3
Survival Rate
Case report of prostate ductal adenocarcinoma presenting with hematuria
Pawlowski, J., Swanson, G. P., Mahalingam, D. & Ha, C. S., Jul 1 2018, In : Urology Case Reports. 19, p. 63-64 2 p.Research output: Contribution to journal › Article
Hematuria
Prostate
Adenocarcinoma
Immunotherapy in colorectal cancer: For the select few or all?
Arora, S. P. & Mahalingam, D., Feb 1 2018, In : Journal of Gastrointestinal Oncology. 9, 1, p. 170-179 10 p.Research output: Contribution to journal › Review article
Immunotherapy
Colorectal Neoplasms
Microsatellite Instability
Therapeutics
Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response
Rosenberg, A. & Mahalingam, D., Feb 1 2018, In : Journal of Gastrointestinal Oncology. 9, 1, p. 143-159 17 p.Research output: Contribution to journal › Review article
Immunotherapy
Adenocarcinoma
Oncolytic Virotherapy
Cancer Vaccines
Tumor Microenvironment
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?
Arora, S. P., Ketchum, N. S., Michalek, J., Gelfond, J. & Mahalingam, D., Sep 1 2018, In : Journal of Gastrointestinal Cancer. 49, 3, p. 283-287 5 p.Research output: Contribution to journal › Article
Clinical Trials, Phase I
Colorectal Neoplasms
Survival
Vascular Endothelial Growth Factor A
Disease-Free Survival